On Dec. 15, 2020, AbCellera Biologics Inc. (“AbCellera” or the “Company”) closed its underwritten initial public offering (the “Offering”) of 27,772,500 common shares, including the exercise in full of the underwriters’ over-allotment option to purchase 3,622,500 additional shares. The common shares were offered to the public at a price of US$20 per common share for aggregate proceeds to the Company of US$555.5 million, before deducting underwriting discounts and commissions and estimated Offering expenses. The common shares were listed on the Nasdaq Global Select Market. The Offering was the largest initial public offering by a Canadian biotechnology company.
Credit Suisse Securities (USA) LLC; Stifel, Nicolaus & Company, Incorporated; Berenberg Capital Markets LLC, SVB Leerink LLC and BMO Capital Markets Corp. acted as joint bookrunning managers for the Offering.
Tryn Stimart, chief legal officer, chief compliance officer and corporate secretary, acted as internal counsel for AbCellera.
Blake, Cassels & Graydon LLP acted as Canadian external counsel for AbCellera, with a team led by
Joseph Garcia,
and which included
Joan Chambers,
Jamie Kariya,
Emma Costante,
Ryan Everett,
Christina Huber.
Goodwin Procter LLP acted as AbCellera’s U.S. counsel with a team led by
Deepa Rich,
Sam Zucker,
James Xu,
Mitch Bloom,
and which included
Kim De Glossop,
Anitha Anne,
Crescent Chasteen,
Grace Wirth,
Jeremy Slotnick,
Alex Varond,
Sarah Wicks,
Dan Karelitz,
Josh Lake,
Kara Kuritz,
Caroline Bullerjahn,
Ettore Santucci,
and with paralegal assistance from
Tricia Hoj,
Ruowen Li.
Cooley LLP represented the underwriters in the U.S. with a team that included
Charlie Kim,
Kristin VanderPas,
Div Gupta,
Rich Segal,
Denny Won,
Pia Kaur,
Ryan Lewis,
Ed Wang,
Dan Hutchins,
Jorge Eduardo Mancillas.
Osler, Hoskin & Harcourt LLP represented the underwriters in Canada with a team that included
Shahir Guindi,
Trevor Scott,
Jeremy Brisset,
Tara Folk,
Ian Morrison (corporate),
Timothy Hughes (tax).